A High Rate of Prescriptions Are Written. The Report examined the number of prescriptions that resulted from patient participation in a Program, concluding that the rate was “high”. In one case, the ...

An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to ...

After a nine-month investigation into direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer, a group of ...

The opportunity to “ talk to a doctor now ” increases access to care, the drug companies say. But the legislators, and some ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major competitor in China.

Shares of Eli Lilly & Co. LLY slid 2.47% to $775.45 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.52% to 6,173.07 ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Meanwhile, Lilly is notching win after win. Eli Lilly's position in the weight management market makes its stock attractive, considering how fast this area is projected to grow in the coming years.

Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics marks a strategic expansion into cardiovascular genetic medicine. The pharmaceutical giant paid a premium of about 113% over Verve’s ...

Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination therapy might change that.

Roshini Raj, associate professor of medicine at NYU Langone Health, joins TODAY to compare the new injectable to others that are already available and shares an update on a trial of Eli Lilly’s ...

Eli Lilly & Co.'s experimental weight loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug's blockbuster potential in the company's ...